Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

This study has been completed.
Sponsor:
Information provided by:
Mylan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01183676
First received: September 24, 2009
Last updated: August 13, 2010
Last verified: August 2010

September 24, 2009
August 13, 2010
July 2007
July 2007   (final data collection date for primary outcome measure)
  • Cmax [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Maximum plasma concentration (micrograms/mL)
  • AUCL [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Area under the concentration time curve from time zero to the last measurable time point. (micrograms x mL/hour)
  • AUCI [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Area under the concentration time curve from time zero to infinity (micrograms x mL/hour)
Same as current
Complete list of historical versions of study NCT01183676 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg
Single-Dose Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets (500 mg; Mylan) and Depakote Tablets (500 mg; Abbott) in Healthy Adult Male And Female (Not of Childbearing Potential) Volunteers

The objective of this study was to investigate the bioequivalence of Mylan's divalproex sodium-delayed-release tablets 500 mg tablets to Abbott's Depakote® 500 mg tablets following a single, oral 500 mg (1 x 500 mg) dose administration under fed conditions.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: DEPAKOTE® Tablets, 500 MG
    1 x 500 mg Tablet, under fed conditions
  • Drug: DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
    1 x 500 mg Tablet, under fed conditions
  • Experimental: Divalproex Sodium
    DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
    Intervention: Drug: DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
  • Active Comparator: Depakote Tablets
    DEPAKOTE® Tablets, 500 MG Abbott Laboratories
    Intervention: Drug: DEPAKOTE® Tablets, 500 MG
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
July 2007
July 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age: 18 years and older.
  2. Sex: Females not of child bearing potential and males.

    • No hormonal contraceptives or hormonal replacement therapies are permitted in this study.
    • Women will not be considered of childbearing potential if one of the following is reported and documented on the medical history:

      • postmenopausal with spontaneous amenorrhea for at least one (1) year, or spontaneous amenorrhea for less than one (1) year with serum FSH levels > 40 mIU/ml, or
      • bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
      • total hysterectomy and an absence of bleeding for at least 3 months.
    • During the course of the study, from study screen until study exit - including the washout period, all men must use a spermicide containing barrier method of contraception in addition to their current contraceptive method. These instructions should be documented in the informed consent form.
  3. Weight Restrictions:

    • At least 60 kg (132 lbs) for men and
    • At least 48 kg (106 lbs) for women
    • All subjects will have a Body Mass Index (BMI) less than or equal to 30 but greater than or equal to 19 (see Part II, Administrative Aspects of Bioequivalence Protocols). BMI values should be rounded to the nearest integer (ex. 30.4 rounds down to 30, while 18.5 rounds up to 19)
  4. All subjects should be judged by the principal or sub-investigator physician listed on the Form FDA 1572 as normal and healthy during a pre-study medical evaluation performed within 21 days of the initial dose of study medication which will include:
  5. Normal or non-clinically significant physical examination including vital signs,
  6. Within normal limits or non-clinically significant laboratory evaluation results for the following tests:

    • Serum Chemistries: sodium, potassium, chloride, BUN, iron, albumin, total protein AST, Alk. Phos., Calcium, Creatinine, ALT, Total bilirubin, Total Cholesterol, Phosphate, Uric Acid, Non-fasting Glucose Triglycerides
    • Hematology: Platelet Count, Hemoglobin, Leukocyte Differential, Hematocrit, Red Blood Cells
    • Urinalysis: Appearance, Specific Gravity, Protein pH, Microscopic Examination
  7. Negative Hepatitis B and Hepatitis C tests,
  8. Negative HIV test,
  9. Normal or non-clinically significant 12-lead ECG
  10. Negative urine drug screen for all of the following compounds: amphetamines, barbiturates, benzodiazepines, cannabinoid, cocaine, methadone, opiates, and phencyclidine

Exclusion Criteria:

  1. Institutionalized subjects will not be used.
  2. Social Habits:

    1. Use of any tobacco-containing products within 1 year of the start of the study.
    2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
    3. Ingestion of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
    4. Any recent, significant change in dietary or exercise habits.
    5. Individual has a history of drug and/or alcohol abuse.
  3. Medications:

    1. Use of any prescription or over-the-counter (OTC) medications within fourteen (14) days prior to the initial dose of study medication.
    2. Use of any hormone replacement therapy within 3 months prior to study medication dosing.
    3. Use of any medication known to induce or inhibit hepatic enzyme activity within 28 days prior to the initial dose of study medication (see Part II, Administrative Aspects of Bioequivalence Protocols for list).
  4. Diseases:

    1. History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, congenital metabolic disorders or neurologic disease.
    2. Acute illness at the time of either the pre-study medical evaluation or dosing.
    3. All laboratory values reflecting hepatic function must be with in 10% of the upper range of normal in order to be considered not clinically significant.
  5. Subjects who have known urea cycle disorders which are a group of uncommon genetic abnormalities (e.g. ornithine transcarbamylase deficiency).
  6. Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.
  7. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
  8. Allergy or hypersensitivity to Divalproex Sodium or any related products.
  9. History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.
  10. Consumption of grapefruit or grapefruit containing products within 7 days of drug administration
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01183676
DIVA-0772
Not Provided
Wayne Talton, Vice President, Regulatory Affairs, Mylan Pharmaceuticals Inc.
Mylan Pharmaceuticals
Not Provided
Not Provided
Mylan Pharmaceuticals
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP